December 6, 2022Annals of OncologyOpen Access

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

View Full Paper

Ask AI

Bookmark

Abstract

With ClinicalTrials.gov NCT02256436 (KEYNOTE-045); https://clinicaltrials.gov/ct2/show/NCT02256436 and NCT02335424 (KEYNOTE-052); https://clinicaltrials.gov/ct2/show/NCT02335424.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Balar et al. (2022) studied this question.

synapsesocial.com/papers/69e005be93e101b251e9c6e4 https://doi.org/10.1016/j.annonc.2022.11.012

View Full Paper

Ask AI

Bookmark

Abstract

With ClinicalTrials.gov NCT02256436 (KEYNOTE-045); https://clinicaltrials.gov/ct2/show/NCT02256436 and NCT02335424 (KEYNOTE-052); https://clinicaltrials.gov/ct2/show/NCT02335424.